AbEx: a novel drug carrier based on human antibody-displaying exosome
Project/Area Number |
24790542
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Applied pharmacology
|
Research Institution | Fukuoka University |
Principal Investigator |
|
Project Period (FY) |
2012-04-01 – 2014-03-31
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2013: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | ドラッグデリバリー / エクソソーム / 抗体 |
Research Abstract |
This study aims to develop a novel DDS utilizing a human antibody-displaying esoxome (AbEx) loaded with exogenous drugs. Because exosomes are able to be prepared from self-derived cells, if antibody to be displayed is produced with fully human V-genes, it is highly unlikely that the AbEx induces a host immune response. Moreover, tumor-specific and effective accumulation of the AbEx is expected to be accomplished by the antibody-directed tumor targeting and the enhanced permeation and retention effect. We successfully constructed a chimeric gene to produce AbEx which displays fusion proteins of a single-chain variable fragment of human anti-carcinoembryonic antigen (CEA) antibody and CD63 on the membrane. It was found that the AbEx actually binds to CEA-expressing cancer cells and is internalized into the cytosol. Unfortunately, the binding specificity was relatively low, we are optimizing the molecular design and expression system for obtaining more functional AbEx.
|
Report
(3 results)
Research Products
(8 results)
-
-
-
-
[Journal Article] Possible therapeutic targets among the molecules involved in the warburg effect in tumor cells.2013
Author(s)
Nam, S O., Yotsumoto, F., Miyata, K., Shirasu, N., Miyamoto, S and Kuroki, Ma.
-
Journal Title
Anticancer Res.
Volume: 33
Pages: 2855-2860
Related Report
Peer Reviewed
-
-
-
-